|Day Low/High||149.55 / 151.58|
|52 Wk Low/High||105.94 / 154.36|
I see there is some debate about IBM in the Diary comments below, and here are my two cents... My biggest gripe with IBM is its inability to harness all of its R&D spending and convert it into revenue. I'm not sure if the management thinks they are...
It's a stock picker's market as action in individual stocks is better than on the indexes.
I don't expect to see the bears and shorts press too hard right now but there isn't going to be much upside momentum.
There are still stock-picking opportunities, but tighten stops and don't let losses build.
Now that the numbers are actually hitting, it's difficult to place faith in possible lower interest rates to offset for poor growth.
The market remains muted on the news, with bad headlines leading to dip-buying and good news failing to produce protracted momentum.
Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.
Don't be rigid in your thesis, keep an eye on market action and respond as appropriate.
It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.
Traders and investors were disappointed recently when the IT company did not raise guidance and that weakness does not look like it has run its course.
IBM is likely to take one of two paths.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
Do we finally have too many new stocks, and are we running out of ammunition to buy them without wholesale liquidation of other stocks?
Oracle tells investors it can regain the crown it once held among enterprises and end-users, but some aren't so sure.
On a historic day when we set new records, let's look at the Dow Jones Industrial Average's Top 10 winners to see how lofty -- or nosebleed -- we really are.
Thanks to strong secular growth trends and perhaps also share gains against major rivals, Adobe and Salesforce are both reporting very strong growth for their marketing software segments.
Like IBM, Larry Ellison's company has begun leaning heavily on layoffs and stock buybacks to boost its EPS in the face of little-to-no revenue growth. It has also relied heavily on M&A over the years to boost sales growth.
Both Washington and Beijing have no shortage of options for inflicting major economic damage on the other party. That provides some reasons to think a near-term truce will eventually be reached, even if there are long-term consequences to this fight.
The blockchain effort could be a necessary step towards the future of global shipping and driving down costs.
I have no idea whether IBM is in the process of a fundamental turnaround, but this point-and-figure price target has my attention.
The security tech firm just reported a major billings decline, issued weak guidance and announced its CEO has resigned. Wall Street has its reasons for giving the company a relatively low valuation.
* I have an outlier and negative view of Apple At the Robin Hood Conference in 2014, I vividly remember the second greatest investor in our generation, Stan Druckenmiller, recommending going long Amazon at $330/share and short IBM at $184/share. Aft...
Warren Buffett is rightly regarded as a genius investor, but traders shouldn't try to time his picks.
From lollipops to locomotives, Warren Buffett's has a full buffet of topics to address Saturday.
Azure and Office 365 were far from the only Microsoft businesses to show good top-line momentum last quarter.
Azure will determine the path that MSFT's stock price will take moving forward.